JPMorgan lowered the firm’s price target on Inspire Medical (INSP) to $54 from $67 and keeps a Neutral rating on the shares. The firm materially cut estimates post the earnings report due to coding uncertainty and WISeR disruption.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $55 from $62 at Evercore ISI
- Inspire Medical price target lowered to $45 from $56 at RBC Capital
- Inspire Medical price target lowered to $55 from $70 at Mizuho
- Inspire Medical price target lowered to $65 from $70 at Stifel
- Piper downgrades Inspire Medical to Neutral on guidance cut